Palo Alto Investors LP - SYNDAX PHARMACEUTICALS INC ownership

SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 85 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.03 and the average weighting 0.3%.

Quarter-by-quarter ownership
Palo Alto Investors LP ownership history of SYNDAX PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$6,862,152
-46.5%
472,600
-22.9%
0.65%
-37.4%
Q2 2023$12,821,718
-0.9%
612,6000.0%1.04%
-3.4%
Q1 2023$12,938,112
-17.0%
612,6000.0%1.07%
-19.3%
Q4 2022$15,590,670
+5.9%
612,6000.0%1.33%
+14.2%
Q3 2022$14,721,000
+24.9%
612,6000.0%1.16%
+13.3%
Q2 2022$11,786,000
+10.7%
612,6000.0%1.03%
+24.8%
Q1 2022$10,647,000
-18.8%
612,600
+2.3%
0.82%
-1.8%
Q4 2021$13,110,000
+54.2%
598,900
+34.6%
0.84%
+63.4%
Q3 2021$8,502,000
+23.4%
444,900
+10.9%
0.51%
+35.0%
Q2 2021$6,887,000
+16.6%
401,100
+51.8%
0.38%
+12.8%
Q1 2021$5,908,000
+0.5%
264,2000.0%0.34%
+9.4%
Q4 2020$5,876,000
+100.7%
264,200
+33.2%
0.31%
+91.3%
Q3 2020$2,928,000
+54.7%
198,400
+55.4%
0.16%
+41.2%
Q2 2020$1,893,000
+161.1%
127,700
+93.2%
0.11%
+86.9%
Q1 2020$725,00066,1000.06%
Other shareholders
SYNDAX PHARMACEUTICALS INC shareholders Q1 2020
NameSharesValueWeighting ↓
Aisling Capital Management LP 1,025,000$24,631,00016.36%
Kynam Capital Management, LP 2,272,915$54,618,00011.51%
Frazier Life Sciences Management, L.P. 3,412,838$82,010,0006.32%
Foresite Capital Management IV, LLC 690,000$16,581,0005.33%
Paradigm Biocapital Advisors LP 1,085,142$26,076,0003.48%
ACUTA CAPITAL PARTNERS, LLC 324,614$7,800,0003.36%
COMMODORE CAPITAL LP 738,110$17,737,0002.85%
SPHERA FUNDS MANAGEMENT LTD. 822,696$19,769,0002.74%
Avidity Partners Management LP 5,586,900$134,253,0002.73%
HealthCor Management, L.P. 859,240$20,648,0002.58%
View complete list of SYNDAX PHARMACEUTICALS INC shareholders